Charles River Q1 revenue $913.9M (+10.8%), GAAP EPS $1.81, non-GAAP EPS $2.75

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2022-Q1 EPS reported $1.81 revenue$913,929,000

Q1 revenue $913.9M (+10.8% YoY); organic growth 9.4%; GAAP net income $93.0M (+51.2%); non-GAAP net income $141.1M (+9.3%).
Segment revenue: RMS $176.5M (flat), DSA $544.3M (+8.6%), Manufacturing $193.1M (+31.8% driven by CDMO acquisitions).
2022 guidance updated: reported revenue growth raised to 13.5%-15.5% (from 13-15%); organic growth unchanged 12.5%-14.5%; non-GAAP EPS reaffirmed $11.50-$11.75.
DSA segment reported record booking activity and strong backlog growth, with studies booked into 2023.
Foreign currency reduced reported revenue growth by 1.7%; acquisitions contributed 4.7%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.